Cell Therapy News

An FDA mandate that requires patients who receive chimeric antigen receptor T-cell therapy to stay within a certain radius of their treatment facility for nearly a month for adverse event monitoring may be overly restrictive.

It’s only the beginning.

Obecabtagene autoleucel conferred durable benefit to certain patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to results of the phase 1B/phase 2 FLEIX study presented at ASCO Annual Meeting.

Several hematologists will be honored during this year’s ASH Annual Meeting.

Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.

Jae Park, MD, compared the moment to a baby being born.

A novel immunotherapy involving HER2-specific chimeric antigen receptor T cells produced clinically beneficial results for multiple individuals with advanced sarcomas, according to results of a phase 1 trial published in Nature Cancer.

CHICAGO — Treatment of with an investigational chimeric antigen receptor T-cell therapy showed an acceptable safety profile and produced durable remissions among certain patients with non-Hodgin lymphoma.

CHICAGO — Combining an mRNA-based cancer vaccine with standard-of-care pembrolizumab significantly improved RFS and distant metastasis-free survival among patients with resected high-risk melanoma, study results showed.

In this episode, host Shikha Jain, MD, speaks with Cyclacel CEO, Spiro Rombotis, MPH, about developing techniques and therapies for drug development, how technology has affected these advancements and more.